Concepedia

Author

Kye Gilder

VistaGen Therapeutics (United States)

Also Known As

K Gilder, K. Gilder, Kye Gilder, Kye M. Gilder

34

Publications

1.1K

Citations

14

H-Index

27

Concepts

All Affiliations

VistaGen Therapeutics (United States)Scripps ClinicArena Pharmaceuticals (United States)Rush University Medical CenterBiogen (United States)
KG

About

Kye Gilder is an author at VistaGen Therapeutics (United States) specializing in medicine, oncology, and cancer therapeutics.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

4

4

218

2

Health Sciences

2

2

35

3

Immunology

2

2

183

4

Gastroenterology

1

1

17

5

Health Policy

1

1

18

Kye Gilder

×

13

Publications

971

Citations

13

H-Index

YearCitations

Long-term Outcomes of the US FDA IDE Prospective, Randomized Controlled Clinical Trial Comparing PCM Cervical Disc Arthroplasty With Anterior Cervical Discectomy and Fusion

Frank M. Phillips, Fred H. Geisler, Kye Gilder,

Spine

2015

228

A Prospective, Randomized, Controlled Clinical Investigation Comparing PCM Cervical Disc Arthroplasty With Anterior Cervical Discectomy and Fusion

Frank M. Phillips, Joe Y.B. Lee, Fred H. Geisler,

Spine

2013

201

A phase II, single-arm study of the anti-α5β1 integrin antibody volociximab as monotherapy in patients with platinum-resistant advanced epithelial ovarian or primary peritoneal cancer

Katherine M. Bell‐McGuinn, Carolyn M. Matthews, Steffan N. Ho,

Gynecologic Oncology

2011

164

Evaluation of the safety of rituximab in combination with a tumor necrosis factor inhibitor and methotrexate in patients with active rheumatoid arthritis: Results from a randomized controlled trial

Maria Greenwald, William Shergy, Jeffrey Kaine,

Arthritis & Rheumatism

2011

93

The relationship between early weight loss and weight loss at 1 year with naltrexone ER/bupropion ER combination therapy

Ken Fujioka, Raymond A Plodkowski, Patrick M. O’Neil,

International Journal of Obesity

2016

84

Method‐of‐use study of naltrexone sustained release (<scp>SR</scp>)/bupropion <scp>SR</scp> on body weight in individuals with obesity

Amy E. Halseth, Kevin Shan, Brandon Walsh,

Obesity

2016

37

Safety, Pharmacokinetics, and Efficacy of Olorinab, a Peripherally Acting, Highly Selective, Full Agonist of the Cannabinoid Receptor 2, in a Phase 2a Study of Patients With Chronic Abdominal Pain Associated With Crohn’s Disease

Bruce Yacyshyn, Stephen B. Hanauer, Preston Klassen,

Crohn s & Colitis 360

2020

37

Quality of life, binge eating and sexual function in participants treated for obesity with sustained release naltrexone/bupropion

Amy E. Halseth, Kevin Shan, Kye Gilder,

Obesity Science & Practice

2018

30

Efficacy and safety of olorinab, a full agonist of the cannabinoid receptor 2, for the treatment of abdominal pain in patients with irritable bowel syndrome: Results from a phase 2b randomized placebo‐controlled trial (<scp>CAPTIVATE</scp>)

Lin Chang, Brooks D. Cash, Anthony Lembo,

Neurogastroenterology & Motility

2023

29

Phase II study comparing volociximab (an antiangiogenic antibody) and pegylated liposomal doxorubicin (PLD) with PLD alone in recurrent ovarian or primary peritoneal cancer

Ignace Vergote, N. Colombo, E. Kutarska,

Journal of Clinical Oncology

2009

19

Page 1